Canada-based Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company with offices in Vancouver and Boston, announced the closing of an upsized underwritten public offering generating approximately USD 747.5 million in gross proceeds before deducting underwriting discounts, commissions, and other expenses. The capital raise comes as the company advances its lead asset, azetukalner, through multiple Phase III clinical programs across epilepsy and psychiatric indications, requiring funding for late-stage development and potential commercialization activities.
The offering consisted of 12,236,843 common shares priced at USD 57.00 per share, which included 1,710,526 additional shares issued upon the full exercise of the underwriters' option to purchase additional shares. Xenon also issued pre-funded warrants to purchase up to 877,194 common shares at a price of USD 56.9999 per warrant, with each warrant carrying an exercise price of USD 0.0001. J.P. Morgan, Jefferies, TD Cowen, Stifel, RBC Capital Markets, and William Blair served as joint book-running managers, while Baird acted as lead manager. The press release did not identify specific end investors or disclose insider participation in the offering.
Company overview and pipeline
Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company headquartered in Vancouver, British Columbia, with additional operations in Boston, Massachusetts. The company's lead molecule, azetukalner (XEN1101), is a KV7 potassium channel opener currently in Phase III clinical development. The compound is being evaluated in multiple indications: a Phase III trial in primary generalized tonic-clonic seizures (the X-ACKT study) is currently recruiting with a target enrollment of 160 patients across sites in the United States, Australia, and Mexico. Azetukalner is also being studied in a Phase III open-label extension trial in bipolar I or II depression (X-CEED-OLE), which is enrolling by invitation with a target of 400 participants. Additional Phase II trials evaluating XEN1101 as adjunctive therapy in focal epilepsy have been conducted across sites in Canada, the United States, Moldova, the United Kingdom, Ukraine, and Spain. The company's earlier-stage pipeline includes KV7 and NaV1.7 ion channel modulators in Phase I development for potential treatment of pain. Completed studies include a Phase II trial of XPF-002 in postherpetic neuralgia and a Phase I/II trial of XPF-002 in inherited erythromelalgia. On the business development side, Xenon maintains an ongoing license and collaboration agreement with Neurocrine Biosciences (Nasdaq: NBIX), originally established in 2019, covering NaV1.6 sodium channel inhibitors for epilepsy. That deal included a USD 50 million upfront payment and up to USD 1.7 billion in potential milestone payments, of which USD 25 million in regulatory milestones had been achieved as of the most recent available disclosures.
Spot something wrong? Report an issue with this article